Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era.
Experimental hematology（2023）
Abstract
•Diffuse large B-cell lymphoma (DLBCL) has a high incidence rate in adults.•About 40% of patients with DLBCL develop refractory or relapse DLBCL, leading to these patients’ death.•Molecular subtyping and prognostic factors can lead to a novel therapeutic approach.•Review of knowledge on prognostic factors might be useful in clinical practice.
MoreTranslated text
Key words
lymphoma,rituximab era,prognostic factors,large b-cell
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined